Alto Neuroscience, Company Leadership
| ANRO Stock | 4.31 0.22 5.38% |
Alto Neuroscience,'s insiders are aggressively buying. The analysis of insiders' sentiment of trading Alto Neuroscience, stock suggests that virtually all insiders are extremely bullish at this time. Alto Neuroscience, employs about 11 people. The company is managed by 11 executives with a total tenure of roughly 0 years, averaging almost 0.0 years of service per executive, having 1.0 employees per reported executive.
Alto Neuroscience,'s Insider Buying Vs Selling
100
Selling | Buying |
Latest Trades
| 2024-07-09 | Adam Savitz | Acquired 12069 @ 12.6 | View | ||
| 2024-03-28 | Nicholas Conrad Smith | Acquired 6150 @ 16.36 | View | ||
| 2024-02-06 | Wave Global Lp Alpha | Acquired 600000 @ 16 | View |
Monitoring Alto Neuroscience,'s insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Alto |
Alto Neuroscience, Management Team Effectiveness
As of the 25th of November 2024, Return On Equity is likely to grow to 0.72, while Return On Tangible Assets are likely to drop (0.44). At this time, Alto Neuroscience,'s Non Current Assets Total are very stable compared to the past year. As of the 25th of November 2024, Other Current Assets is likely to grow to about 3.4 M, while Total Assets are likely to drop about 61 M. Alto Neuroscience,'s management efficiency ratios could be used to measure how well Alto Neuroscience, manages its routine affairs as well as how well it operates its assets and liabilities.As of the 25th of November 2024, Common Stock Shares Outstanding is likely to drop to about 28.6 M
Alto Neuroscience, Workforce Comparison
Alto Neuroscience, is currently under evaluation in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 890. Alto Neuroscience, adds roughly 0.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Alto Neuroscience, Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Alto Neuroscience, insiders, such as employees or executives, is commonly permitted as long as it does not rely on Alto Neuroscience,'s material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Alto Neuroscience, insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Savitz Adam over two months ago Acquisition by Savitz Adam of 10681 shares of Alto Neuroscience, at 12.53 subject to Rule 16b-3 | ||
Savitz Adam over three months ago Acquisition by Savitz Adam of 2931 shares of Alto Neuroscience, at 13.22 subject to Rule 16b-3 | ||
Alpha Wave Global Lp over six months ago Conversion by Alpha Wave Global Lp of 1962995 shares of ANRO | ||
Chen Po Yu Jeff over six months ago Conversion by Chen Po Yu Jeff of 259 shares of ANRO | ||
Chen Po Yu Jeff over six months ago Acquisition by Chen Po Yu Jeff of 30574 shares of ANRO subject to Rule 16b-3 | ||
Alkeon Capital Management Llc over six months ago ANRO exotic insider transaction detected |
Alto Neuroscience, Notable Stakeholders
An Alto Neuroscience, stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Alto Neuroscience, often face trade-offs trying to please all of them. Alto Neuroscience,'s stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Alto Neuroscience,'s stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Wei Wu | CoFounder Officer | Profile | |
| B BCom | CoFounder CEO | Profile | |
| Amit MD | Chairman Founder | Profile | |
| Nicholas Smith | CFO Secretary | Profile | |
| Melissa Berman | Vice Accounting | Profile | |
| Michael MBA | Chief Officer | Profile | |
| Jason Hoffman | Vice Resources | Profile | |
| Erin JD | General Officer | Profile | |
| Adam MD | Chief Officer | Profile | |
| Fadi MD | Senior Innovation | Profile | |
| Jessica Powell | Chief Officer | Profile |
About Alto Neuroscience, Management Performance
The success or failure of an entity such as Alto Neuroscience, often depends on how effective the management is. Alto Neuroscience, management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Alto management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Alto management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.42) | (0.44) | |
| Return On Capital Employed | (0.47) | (0.49) | |
| Return On Assets | (0.42) | (0.44) | |
| Return On Equity | 0.51 | 0.72 |
Alto Neuroscience, Workforce Analysis
Traditionally, organizations such as Alto Neuroscience, use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Alto Neuroscience, within its industry.Alto Neuroscience, Manpower Efficiency
Return on Alto Neuroscience, Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 3.3M | |
| Net Loss Per Executive | 3.3M | |
| Working Capital Per Employee | 7.3M | |
| Working Capital Per Executive | 7.3M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alto Neuroscience,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Alto Stock, please use our How to Invest in Alto Neuroscience, guide.You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alto Neuroscience,. If investors know Alto will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alto Neuroscience, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.85) |
The market value of Alto Neuroscience, is measured differently than its book value, which is the value of Alto that is recorded on the company's balance sheet. Investors also form their own opinion of Alto Neuroscience,'s value that differs from its market value or its book value, called intrinsic value, which is Alto Neuroscience,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alto Neuroscience,'s market value can be influenced by many factors that don't directly affect Alto Neuroscience,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alto Neuroscience,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Alto Neuroscience, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alto Neuroscience,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.